HLA半相合异基因外周血造血干细胞移植治疗AA克隆演变继发MDS疗效分析
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金青年基金(81400079);江苏省卫计委项目(Z201402);江苏省科教强卫工程医学青年人才 (QNRC2016565);江苏省六大人才高峰(WSN?026)


Efficiency and safty of haploidentical hematopoietic stem cell transplantation for myelodysplastic syndrome evolved from aplastic anemia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:回顾性分析应用HLA半相合异基因外周血造血干细胞移植(haploidentical hematopoietic stem cell transplantation,haplo-HSCT)治疗再生障碍性贫血(aplastic anemia,AA)克隆演变继发骨髓增生异常综合征(secondary myelodysplastic syndrome,sMDS)的疗效和安全性。方法:本中心5例AA患者经强化免疫抑制治疗后演变为sMDS,均采用haplo-HSCT,观察植入情况,移植物抗宿主病(graft versus host disease,GVHD)、移植相关并发症和移植相关病死率(transplant related modify,TRM)、总体生存(overall survival,OS)时间等。结果:5例中位OS时间63个月(41.9~149.3个月),移植后中位OS时间12.9个月(2.4~36.5个月),1年累积生存率60%,TRM 40%。移植后粒系植入时间18 d(14~22 d),血小板植入时间21 d(15~65 d),总植入率100%。60%(3/5)患者发生Ⅰ~Ⅲ度急性移植物抗宿主病(acute graft versus host disease,aGVHD),无Ⅳ度aGVHD发生,20%(1/5)患者发生慢性移植物抗宿主病(chronic graft versus host disease,cGVHD)。中位随访时间63个月(41.9~149.3个月)。结论:在无合适HLA相合供者情况下,haplo-HSCT可作为AA演变MDS患者的有效治疗策略。

    Abstract:

    Objective:To evaluate the efficiency and safety of haploidentical hematopoietic stem cell transplantation(haplo-HSCT)for treatment of secondary myelodysplastic syndrome(sMDS) after AA. Methods:Evaluation of therapeutic effect,incidence rate of aGVHD and cGVHD,complications and overall survival(OS) of 5 AA post MDS patients who received haplo-HSCT in this center,and compared with other treatments for sMDS evolved from AA. Results:Among 5 patients,median OS was 63 months(range from 41.9 to 149.3 months),OS after HSCT was 12.9 months(range from 2.4 to 36.5 months). 1-year event free survival was 60%. All patients achieved neutrophil and platelet engraftment at a median of 18 days(range from 14 to 22 days)and 21 days(range from 15 to 65 days)respectively. 3 occurred Ⅰ~Ⅲ° acute graft versus host disease(aGVHD),and 1 with chronic graft versus host disease(cGVHD). Medial follow-up was 63 months(range from 41.9 to 149.3 months). Conclusion:The haplo-HSCT can be an opition for sMDS from AA patients in case of an HLA-identical donor is not available.

    参考文献
    相似文献
    引证文献
引用本文

黄 菲,张 闰,缪扣荣,吴汉新,沈文怡,陆 化. HLA半相合异基因外周血造血干细胞移植治疗AA克隆演变继发MDS疗效分析[J].南京医科大学学报(自然科学版),2018,(9):1269-1274

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2018-03-23
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2018-09-17
  • 出版日期: